Biotechnology company OMass Therapeutics has raised $310 million as part of an oversubscribed Series C financing round.  The funding will be used to support the advancement of the company’s lead programme into Phase II clinical development.   The company’s lead compound, OMS1620, is a potential best-in-class MC2 (melanocortin-2) receptor antagonist targeting congenital adrenal hyperplasia (CAH) and ACTH-dependent […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!